Literature DB >> 23725108

Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy.

Yan-Jie Chen1, Yu-Shui Ma, Ying Fang, Yi Wang, Da Fu, Xi-Zhong Shen.   

Abstract

Ubiquitin carboxyl-terminal hydrolase 37 (UCH37, also called UCHL5), a member of the deubiquitinating enzymes, can suppress protein degradation through disassembling polyubiquitin from the distal subunit of the chain. It has been proved that UCH37 can be activated by proteasome ubiqutin chain receptor Rpn13 and incorporation into the 19S complex. UCH37, which has been reported to assist in the mental development of mice, may play an important role in oncogenesis, tumor invasion and migration. Further studies will allow a better understanding of roles in cell physiology and pathology, embryonic development and tumor formation, hopefully providing support for the idea that UCH37 may constitute a new interesting target for the development of anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23725108     DOI: 10.7314/apjcp.2013.14.4.2173

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  12 in total

1.  Modeling the structural and reactivity properties of hydrazono methyl-4H-chromen-4-one derivatives-wavefunction-dependent properties, molecular docking, and dynamics simulation studies.

Authors:  Y Sheena Mary; Y Shyma Mary; K S Resmi; S Sarala; Rohitash Yadav; Ismail Celik
Journal:  J Mol Model       Date:  2021-05-26       Impact factor: 1.810

2.  High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer.

Authors:  Lin Wang; Yan-Jie Chen; Kai Xu; Ya-Yun Wang; Xi-Zhong Shen; Rui-Qin Tu
Journal:  Tumour Biol       Date:  2014-08-15

Review 3.  Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

Authors:  Kush Patel; Zainab So Ahmed; Xuemei Huang; Qianqian Yang; Elmira Ekinci; Christine M Neslund-Dudas; Bharati Mitra; Fawzy Aem Elnady; Young-Hoon Ahn; Huanjie Yang; Jinbao Liu; Qing Ping Dou
Journal:  Future Med Chem       Date:  2018-08-01       Impact factor: 3.808

4.  Structural basis for the activation and inhibition of the UCH37 deubiquitylase.

Authors:  Ryan T Vander Linden; Casey W Hemmis; Benjamin Schmitt; Ada Ndoja; Frank G Whitby; Howard Robinson; Robert E Cohen; Tingting Yao; Christopher P Hill
Journal:  Mol Cell       Date:  2015-02-19       Impact factor: 17.970

5.  Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells.

Authors:  Zainab Sabry Othman Ahmed; Xin Li; Feng Li; Hassan Ali Cheaito; Kush Patel; El-Sayed Mohammed Mosallam; Gehad Abd El-Fattah Hassan Elbargeesy; Q Ping Dou
Journal:  J Cell Biochem       Date:  2018-07-17       Impact factor: 4.429

6.  Naturally Occurring Isothiocyanates Exert Anticancer Effects by Inhibiting Deubiquitinating Enzymes.

Authors:  Ann P Lawson; Marcus J C Long; Rory T Coffey; Yu Qian; Eranthie Weerapana; Farid El Oualid; Lizbeth Hedstrom
Journal:  Cancer Res       Date:  2015-11-05       Impact factor: 12.701

Review 7.  Meddling with Fate: The Proteasomal Deubiquitinating Enzymes.

Authors:  Stefanie A H de Poot; Geng Tian; Daniel Finley
Journal:  J Mol Biol       Date:  2017-10-05       Impact factor: 5.469

8.  Ubiquitin carboxyl-terminal hydrolase isozyme L5 inhibits human glioma cell migration and invasion via downregulating SNRPF.

Authors:  Jiafeng Ge; Weiwei Hu; Hui Zhou; Juan Yu; Chongran Sun; Weilin Chen
Journal:  Oncotarget       Date:  2017-12-07

9.  Identification of deubiquitinase targets of isothiocyanates using SILAC-assisted quantitative mass spectrometry.

Authors:  Ann P Lawson; Daniel W Bak; D Alexander Shannon; Marcus J C Long; Tushara Vijaykumar; Runhan Yu; Farid El Oualid; Eranthie Weerapana; Lizbeth Hedstrom
Journal:  Oncotarget       Date:  2017-04-20

10.  Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma.

Authors:  Huiqiong Yang; Yusheng Li; Xiaoming Zhong; Pei Luo; Ping Luo; Ran Sun; Ruting Xie; Da Fu; Yushui Ma; Xianling Cong; Wenping Li
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.